Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial

NACompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions
Gram-negative BacteremiaBloodstream Infection
Interventions
DIAGNOSTIC_TEST

Reveal

Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).

Trial Locations (7)

12462

Attikon University General Hospital, Chaïdári

15006

Complexo Hospitalario Universitario A Coruña (CHUAC) Sergas, A Coruña

18536

Tzaneio General Hospital, Piraeus

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

575001

Kasturba Medical College, Mangalore, Attavāra

3109601

Rambam Health Care Campus, Haifa

4428162

Meir Medical Center, Kfar Saba

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Parexel

INDUSTRY

collaborator

BioMérieux

INDUSTRY

lead

Duke University

OTHER

NCT06174649 - Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial | Biotech Hunter | Biotech Hunter